Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Biological Vaccine VLA1553 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VLA1553 Lot 1 | ACTIVE_COMPARATOR | - |
| VLA1553 Lot 2 | ACTIVE_COMPARATOR | - |
| VLA1553 Lot 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Biological Vaccine VLA1553 | BIOLOGICAL | Single intramuscular vaccination on Day 1 with one of three Lots of VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate |
Inclusion Criteria: 1. 18 to 45 years of age on the Day of screening 2. Able to provide informed consent 3. Generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests 4. For women of childbearing potential: ...
VLA1553 is an investigational vaccine candidate being developed for the prevention of Chikungunya virus infection. It is a live-attenuated vaccine designed to protect against the mosquito-borne viral disease. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
VLA1553 is being developed by Valneva SE, a biopharmaceutical company. Valneva is publicly traded on the NASDAQ under the ticker symbol VALN. The company is conducting clinical trials to evaluate the safety and efficacy of this vaccine candidate for Chikungunya virus infection.
VLA1553 is in Phase 3 clinical development. It is an investigational vaccine candidate and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine remains under evaluation for the prevention of Chikungunya virus infection.
VLA1553 has been evaluated in one completed Phase 3 clinical trial registered as NCT04786444. This study, titled 'Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults,' enrolled 409 participants in the United States. The trial was randomized, double-blind, and active-controlled.
Yes, VLA1553 is a live-attenuated chikungunya virus vaccine candidate. It is designed to elicit an immune response against the Chikungunya virus. The vaccine is being developed by Valneva SE and has completed a Phase 3 clinical trial to evaluate its consistency and immunogenicity in healthy adults.